Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic

The rapid global spread of SARS-CoV-2 (COVID-19) in March 2020 led to major changes to stem cell donor availability and product transportation. Transplantation organizations throughout the world responded by recommending cryopreservation of all unrelated donor hemopoietic progenitor cell (HPC) products before commencing recipient conditioning [1 –4]. Although necessary to enable continued access to unrelated donors, routine cryopreservation may introduce additional risks to both donor and recipient.

Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Authors: Duncan Purtill, Cheryl Hutchins, Glen Kennedy, Andrea McClean, Chris Fraser, Peter J Shaw, Paul Chiappini, Helen Tao, David Ma, Karieshma Kabani, Lijun Bai, Matthew Greenwood, Ashish Bajel, Elizabeth O'Flaherty, David Curtis, Leanne Purins, Travis Perera, Source Type: research